Cipla Ltd
BSE:500087

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
BSE:500087
Watchlist
Price: 1 313.75 INR -0.08%
Market Cap: ₹1.1T

Net Margin

16%
Current
Improving
by 0.1%
vs 3-y average of 16%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16%
=
Net Income
₹45.5B
/
Revenue
₹283.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16%
=
Net Income
₹45.5B
/
Revenue
₹283.5B

Peer Comparison

Country Company Market Cap Net
Margin
IN
Cipla Ltd
NSE:CIPLA
1.1T INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
530.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP
Loading...
CH
Novartis AG
SIX:NOVN
222.3B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
267.6B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.1B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.2B EUR
Loading...

Market Distribution

Higher than 79% of companies in India
Percentile
79th
Based on 5 531 companies
79th percentile
16%
Low
-305 007.7% — 2.1%
Typical Range
2.1% — 11.6%
High
11.6% — 1 221 633.3%
Distribution Statistics
India
Min -305 007.7%
30th Percentile 2.1%
Median 5.8%
70th Percentile 11.6%
Max 1 221 633.3%

Cipla Ltd
Glance View

In the bustling heart of India's pharmaceutical landscape, Cipla Ltd. stands as a venerable name, tracing its roots back to 1935. Founded by Khwaja Abdul Hamied, Cipla embarked on a journey fueled by the vision of making healthcare accessible and affordable to the masses. Over decades, the company has morphed into a global pharmaceutical powerhouse, seamlessly integrating science and compassion. Cipla primarily operates through the production and sale of active pharmaceutical ingredients (APIs) and a wide array of generic medicines, catering to various therapeutic segments such as respiratory, anti-retroviral, urology, cardiology, and oncology. The company’s manufacturing prowess is underpinned by its state-of-the-art facilities, strategically located to serve markets across the globe, ensuring its competitive edge in quality and cost-efficiency. Cipla's revenue streams elegantly dance around its core philosophy—offering affordable medication without compromising quality. The company capitalizes on its robust R&D capabilities to develop and market generics that serve as cost-effective alternatives to patented medicines. Its business model thrives on the volume-driven sale of these generics, both in domestic and international markets. Additionally, Cipla reinforces its revenue through strategic partnerships and collaborations across the pharmaceutical value chain, and by out-licensing its products in various regions. By continually expanding its pipeline to include biosimilars and new drug delivery systems, Cipla not only strengthens its foothold in existing markets but also pioneers growth into new pharmaceutical frontiers.

CIPLA Intrinsic Value
1 268.25 INR
Overvaluation 3%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
16%
=
Net Income
₹45.5B
/
Revenue
₹283.5B
What is Cipla Ltd's current Net Margin?

The current Net Margin for Cipla Ltd is 16%, which is above its 3-year median of 16%.

How has Net Margin changed over time?

Over the last 3 years, Cipla Ltd’s Net Margin has increased from 11.8% to 16%. During this period, it reached a low of 11.8% on Dec 31, 2022 and a high of 19.4% on Jun 30, 2025.

Back to Top